Stay updated with breaking news from Ephio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Phio Pharmaceuticals (NASDAQ:PHIO – Free Report) had its price objective reduced by HC Wainwright from $6.00 to $4.00 in a report released on Tuesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Phio Pharmaceuticals’ Q4 2023 earnings at ($1.30) EPS, FY2023 earnings at ($6.26) […] ....
Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Get Free Report) was the target of a significant growth in short interest in December. As of December 15th, there was short interest totalling 124,600 shares, a growth of 783.7% from the November 30th total of 14,100 shares. Based on an average daily trading volume, of 1,480,000 shares, the days-to-cover […] ....
By Josh Beckerman Phio Pharmaceuticals shares rose 60% after the company reported favorable data from two preclinical studies of cancer drug PH-894. The. ....
Ericsson said that running ‘Ericsson Cloud RAN’ on GDC Edge will enable telcos to utilise Google Cloud Vertex AI, BigQuery, and other cloud services, to improve the usability of the massive data sets being provided by Cloud RAN applications. ....
Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Get Free Report) saw a large increase in short interest in August. As of August 31st, there was short interest totalling 14,700 shares, an increase of 19.5% from the August 15th total of 12,300 shares. Currently, 0.7% of the shares of the stock are sold short. Based on an average […] ....